Balloon pulmonary angioplasty in the current era of CTEPH treatment: How did we get here?
Abstract Chronic thromboembolic pulmonary hypertension (CTEPH) is caused by persistent organized thromboembolic obstruction of the pulmonary arteries from incompletely resolved pulmonary embolism. The treatment of choice is pulmonary thromboendarterectomy (PTE) surgery and all patients should be eva...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-10-01
|
Series: | Pulmonary Circulation |
Subjects: | |
Online Access: | https://doi.org/10.1002/pul2.12312 |
_version_ | 1827396464859414528 |
---|---|
author | Jenny Z. Yang David S. Poch Lawrence Ang Ehtisham Mahmud Nick H. Kim |
author_facet | Jenny Z. Yang David S. Poch Lawrence Ang Ehtisham Mahmud Nick H. Kim |
author_sort | Jenny Z. Yang |
collection | DOAJ |
description | Abstract Chronic thromboembolic pulmonary hypertension (CTEPH) is caused by persistent organized thromboembolic obstruction of the pulmonary arteries from incompletely resolved pulmonary embolism. The treatment of choice is pulmonary thromboendarterectomy (PTE) surgery and all patients should be evaluated for operability candidacy. Despite advancements in PTE technique allowing more segmental–subsegmental surgeries, up to a third of patients with CTEPH may still be considered inoperable. Over the past decade, there have been increasing treatment options for these inoperable CTEPH patients. Balloon pulmonary angioplasty (BPA) is a percutaneous‐based interventional treatment option for select CTEPH cases. Early BPA experiences were plagued by high complication rates, but further refinements in technique and equipment pioneered by Japan led to the worldwide spread and adoption of BPA. Multiple centers have shown that patients experience significant improvements in hemodynamics, quality of life, exercise capacity, and survival with BPA treatment. There remain many questions on best practices, but BPA has evolved into a pivotal cornerstone of CTEPH treatment. |
first_indexed | 2024-03-08T18:51:22Z |
format | Article |
id | doaj.art-c76824ada7b54539b46d418ae6621ce6 |
institution | Directory Open Access Journal |
issn | 2045-8940 |
language | English |
last_indexed | 2024-03-08T18:51:22Z |
publishDate | 2023-10-01 |
publisher | Wiley |
record_format | Article |
series | Pulmonary Circulation |
spelling | doaj.art-c76824ada7b54539b46d418ae6621ce62023-12-28T19:02:35ZengWileyPulmonary Circulation2045-89402023-10-01134n/an/a10.1002/pul2.12312Balloon pulmonary angioplasty in the current era of CTEPH treatment: How did we get here?Jenny Z. Yang0David S. Poch1Lawrence Ang2Ehtisham Mahmud3Nick H. Kim4Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine UC San Diego La Jolla California USADepartment of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine UC San Diego La Jolla California USADepartment of Medicine, Division of Cardiovascular Medicine UC San Diego La Jolla California USADepartment of Medicine, Division of Cardiovascular Medicine UC San Diego La Jolla California USADepartment of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine UC San Diego La Jolla California USAAbstract Chronic thromboembolic pulmonary hypertension (CTEPH) is caused by persistent organized thromboembolic obstruction of the pulmonary arteries from incompletely resolved pulmonary embolism. The treatment of choice is pulmonary thromboendarterectomy (PTE) surgery and all patients should be evaluated for operability candidacy. Despite advancements in PTE technique allowing more segmental–subsegmental surgeries, up to a third of patients with CTEPH may still be considered inoperable. Over the past decade, there have been increasing treatment options for these inoperable CTEPH patients. Balloon pulmonary angioplasty (BPA) is a percutaneous‐based interventional treatment option for select CTEPH cases. Early BPA experiences were plagued by high complication rates, but further refinements in technique and equipment pioneered by Japan led to the worldwide spread and adoption of BPA. Multiple centers have shown that patients experience significant improvements in hemodynamics, quality of life, exercise capacity, and survival with BPA treatment. There remain many questions on best practices, but BPA has evolved into a pivotal cornerstone of CTEPH treatment.https://doi.org/10.1002/pul2.12312balloon pulmonary angioplastyBPAchronic thromboembolic pulmonary diseaseCTEPHpulmonary vascular |
spellingShingle | Jenny Z. Yang David S. Poch Lawrence Ang Ehtisham Mahmud Nick H. Kim Balloon pulmonary angioplasty in the current era of CTEPH treatment: How did we get here? Pulmonary Circulation balloon pulmonary angioplasty BPA chronic thromboembolic pulmonary disease CTEPH pulmonary vascular |
title | Balloon pulmonary angioplasty in the current era of CTEPH treatment: How did we get here? |
title_full | Balloon pulmonary angioplasty in the current era of CTEPH treatment: How did we get here? |
title_fullStr | Balloon pulmonary angioplasty in the current era of CTEPH treatment: How did we get here? |
title_full_unstemmed | Balloon pulmonary angioplasty in the current era of CTEPH treatment: How did we get here? |
title_short | Balloon pulmonary angioplasty in the current era of CTEPH treatment: How did we get here? |
title_sort | balloon pulmonary angioplasty in the current era of cteph treatment how did we get here |
topic | balloon pulmonary angioplasty BPA chronic thromboembolic pulmonary disease CTEPH pulmonary vascular |
url | https://doi.org/10.1002/pul2.12312 |
work_keys_str_mv | AT jennyzyang balloonpulmonaryangioplastyinthecurrenteraofctephtreatmenthowdidwegethere AT davidspoch balloonpulmonaryangioplastyinthecurrenteraofctephtreatmenthowdidwegethere AT lawrenceang balloonpulmonaryangioplastyinthecurrenteraofctephtreatmenthowdidwegethere AT ehtishammahmud balloonpulmonaryangioplastyinthecurrenteraofctephtreatmenthowdidwegethere AT nickhkim balloonpulmonaryangioplastyinthecurrenteraofctephtreatmenthowdidwegethere |